MPM Oncology Impact Management »

Fulcrum Therapeutics shares owned by MPM Oncology Impact Management

Quarter-by-quarter ownership of Fulcrum Therapeutics (FULC) shares owned by MPM Oncology Impact Management from 13F filings

Historical chart of MPM Oncology Impact Management investment in Fulcrum Therapeutics

Tip: Access up to 7 years of quarterly data

All positions including Fulcrum Therapeutics held by MPM Oncology Impact Management consolidated in one spreadsheet with up to 7 years of data

Download as csvDownload consolidated filings csv Download as ExcelDownload consolidated filings xlsx

Quarterly reported holdings in Fulcrum Therapeutics by MPM Oncology Impact Management

Quarter filed Position value Share count Share price at filing
2024-06-30 $9.0M 1.4M 6.20
2024-03-31 $11M 1.1M 9.44

More positions owned by MPM Oncology Impact Management

Cullinan Therapeutics Common (CGEM)
Insmed Incorporated Common (INSM)
Olema Pharmaceuticals Common (OLMA)
iTeos Therapeutics Common (ITOS)
Crinetics Pharmaceuticals Common (CRNX)
Madrigal Pharmaceuticals Common (MDGL)
Iovance Biotherapeutics Common (IOVA)
Natera Common (NTRA)
Mirum Pharmaceuticals Common (MIRM)
Ultragenyx Pharmaceutical Common (RARE)
Moonlake Immunotherapeutics Class A Ord (MLTX)
Guardant Health Common (GH)
Disc Medicine Common (IRON)
Alkermes Common (ALKS)
Edgewise Therapeutics Common (EWTX)

View all positions for MPM Oncology Impact Management

Top funds holding Fulcrum Therapeutics

RA Capital Management
BlackRock
Vanguard Group
Cowen And Company
Caption Management
Suvretta Capital Management
Trv Gp Iv
Citadel Advisors
Logos Global Management
Dimensional Fund Advisors
MPM Oncology Impact Management
Leucadia National Corporation
Geode Capital Management
Morgan Stanley
Vestal Point Capital

View all funds holding Fulcrum Therapeutics